医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mystic Pharmaceuticals Receives Notices of Allowance from Japan and China on Drug Delivery Platform Technologies

2013年10月01日 PM07:25
このエントリーをはてなブックマークに追加


 

AUSTIN, Texas

Mystic Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, announced today it has received Notices of Allowance from the China Patent Office for its “Deep Draw Container Forming Method” (invention number ZL200880106965.1) and the Japan Patent Office for its “Combination Unit Dose Dispensing Container” (application number 2010-508588) patent applications. Mystic’s VersiDoser® and VRx2™ delivery technologies are used in combination with drugs and biologics to develop therapeutics for the treatment of ocular, CNS, neurodegenerative and infectious diseases affecting large global populations.

Timothy Sullivan, Mystic’s President and CEO, stated that, “Over the past decade Mystic has innovated packaging and delivery technologies that enable the development of patient-centric pharmaceutical products. Japan and China along with several other global markets are high priority strategic opportunities for Mystic enhanced pharmaceutical drug/device combined products. These latest international patents reflect our long term commitment to developing the global market opportunity for our technology and products.” Mystic’s VersiDoser® and VRx2™ delivery platforms utilize novel unit dose packaging and patient-centric dispensers that can be configured for precision self-administration of therapeutics for ophthalmic, systemic nasal, nose to brain, sublingual, oral and dermal applications.

Mystic’s delivery platform technologies enable pharmaceutical and biotech manufacturers to develop patient-oriented products that can extend or establish market exclusivity and competitive differentiation for new or existing drugs and biologics. The shift to patient-centric products benefits the consumer through improved compliance and health outcomes while building brand value for the pharmaceutical manufacturer. Mystic’s delivery platforms and products are designed to meet the diverse demands of consumers and pharma manufacturers in the globally competitive market.

About Mystic Pharmaceuticals, Inc.

Mystic Pharmaceuticals™ is an integrated specialty pharmaceutical company based in Austin, Texas. Mystic provides patient-centric pharmaceutical products and delivery technology and for pharmaceuticals, biopharmaceuticals and biologics for intranasal, ophthalmic, sublingual, dermal and otic applications. Mystic combines its novel delivery systems with pharmaceuticals and biologics under development by Mystic and its partners, to meet the expanding global market demand for healthcare products that are safer, simpler to use and cost effective. For more information please visit the Mystic website: www.mysticpharmaceuticals.com.

CONTACT

Mystic Pharmaceuticals, Inc.
Melissa Brandt, +1-512-918-2900 ext.
224
mbrandt@mysticpharmaceuticals.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists